Greenwich LifeSciences, Inc. (GLSI)

Market Cap	113.58M
Revenue (ttm)	n/a
Net Income (ttm)	-8.86M
Shares Out	12.85M
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,815
Open	8.73
Previous Close	8.78
Day's Range	8.60 - 8.85
52-Week Range	8.19 - 21.50
Beta	3.14
Analysts	Strong Buy
Price Target	38.00 (+329.86%)
Earnings Date	Nov 13, 2023

About GLSI

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is h...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: GLSI

Analyst Forecast

According to one analyst, the rating for GLSI stock is "Strong Buy" and the 12-month stock price forecast is $38.0.

Price Target

$38.0

(329.86% upside)

Analyst Consensus: Strong Buy